×

Biotech and Pharmaceuticals Pharmaceuticals

  • WASHINGTON, Feb 13- Marathon Pharmaceuticals LLC said on Monday it was "pausing" the launch of its Duchenne muscular dystrophy drug after U.S. lawmakers questioned why the company priced it at $89,000 a year when patients had been able to import it for as little as $1,000. Marathon's drug, Emflaza, known generically as deflazacort, is a steroid, one of a class of drugs...

  • WASHINGTON, Feb 13- Two U.S. lawmakers have called on privately held Marathon Pharmaceuticals LLC to explain how it came to price its newly approved drug to treat Duchenne muscular dystrophy at $89,000 a year when patients have for decades been able to acquire it overseas for as little as $1,000. The drug, Emflaza, known generically as deflazacort, is a steroid, one...

  • U.S. Democratic presidential candidate Bernie Sanders.

    Marathon says it will charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.

  • LONDON, Feb 13- European shares gained on Monday as mining stocks touched a 2 1/ 2- year high on rising copper prices and mergers and acquisitions continued to drive shares, with takeover offers sending German drugmaker Stada to a record high. It led sectoral gainers in Europe as copper prices hit their highest in 20 months in heavy trade, driven up by supply worries...

  • FRANKFURT, Feb 13- Stada has invited rival suitors Cinven Partners and Advent International to the negotiating table, the German generic drugs and consumer care group said on Monday, after months of courtship. Stada's share price, inflated by persistent takeover speculation, and opposition from supervisory board chairman Carl Ferdinand Oetker, part of the...

  • The Allergan post at the New York Stock Exchange.

    Allergan said it would buy Zeltiq Aesthetics for about $2.48 billion to gain access to its flagship body contouring technology.

  • A banner displays a Teva Pharmaceutical Industries Ltd. logo at the entrance to the company's new factory in Godollo, Hungary.

    Teva earned $1.38 per share, up from $1.28. Revenue grew 33 percent to $6.5 billion, primarily due to the $630 million from the Actavis acquisition.

  • A patient with Duchenne muscular dystrophy controls a motorized wheelchair. DMD afflicts about 1 in 3,500 boys worldwide.

    Marathon said the muscular dystrophy drug will cost $89,000 a year, but that the company will provide a "robust" assistance program for uninsured patients.

  • Feb 13- The prospect of a bidding war drove shares in Stada 14 percent higher on Monday after the German drugmaker said it was weighing two takeover approaches, including one from private equity firm Cinven Partners which valued it at almost 3.5 billion euros. Cinven itself had been preparing a joint bid with Poland's unlisted Polpharma SA to combine the two...

  • MILAN, Feb 13- European shares rose for a fifth consecutive session on Monday with mining stocks touching their highest in 2-1/ 2- years on stronger copper prices and with takeover offers sending German drugmaker Stada to a record high. UK's FTSE was up 0.1 percent. It led sectoral gainers in Europe as copper prices hit their highest in 20 months in heavy trade,...

  • PBMs are able to negotiate on drug prices: Dave Dorman

    Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.

  • MUMBAI, Feb 10- Indian drugmaker Aurobindo Pharma plans to set up a factory in the United States for injectable products, it said on Friday, days after U.S. His comments have worried some in India's roughly $15 billion pharmaceutical industry which supplies about 30 percent of the medicines sold in the United States and relies on the country for the bulk of its...

  • Feb 9- Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments. Eylea has powered much of the company's explosive growth since late 2011, but sales growth in the United States has...

  • Martin Shkreli

    The pharma bro Shkreli previously won permission to speak at two other universities, but neither event happened because of protests.

  • *Q4 revenue rises 11.7 pct to $45.97 bln vs. est. Q4 earnings $1.71 per share vs. est. "We are the solution and not the problem," CVS's Chief Executive Larry Merlo said, noting that numerous evaluations from government agencies have concluded that PBMs drive real savings to the healthcare sector.

  • The company's pharmacy services unit revenue rose about 18 percent to $31.26 billion in the fourth quarter ended Dec. 31, primarily driven by growth in its pharmacy network and specialty pharmacy claims. Net income attributable to CVS rose to $1.71 billion, or $1.59 per share, in the quarter, from about $1.50 billion, or $1.34 per share, a year earlier.

  • NEW YORK, Feb 8- Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved. "The FDA has been very supportive of getting new antibiotics approved, so clearly we have a fast-track agreement with them once we get...

  • Martin Shkreli, former Chief Executive Officer of Turing Pharmaceuticals

    A new SEC filing shows that Shkreli is involved in a tech start-up whose executives include a long-time Shkreli associate.

  • Sales of the drugs, including Sovaldi and Harvoni, have slowed, missing Wall Street estimates in the past few quarters, but still account for nearly half of Gilead's total revenue. Chief Executive John Milligan acknowledged on Tuesday that the company had few prospects for new products over the next few years. The company had $32.4 billion of cash, cash...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...